NCT04727645

Brief Summary

The perpuse of this study is to investigate the feasibility of the Philips interventional MRI suite "iSuite" to create an electroanatomical map of the heart based on which the real-time location of the catheters can be correctly and reliably visualized during CMR-guided electrophysiological procedure (CMR-EP).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 4, 2021

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

January 18, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 27, 2021

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

February 3, 2023

Status Verified

February 1, 2023

Enrollment Period

3.4 years

First QC Date

January 18, 2021

Last Update Submit

February 2, 2023

Conditions

Keywords

Cardiac Magnetic Resonance Imaging (CMR)CMR-guided electrophysiological procedureRadiofrequency ablation

Outcome Measures

Primary Outcomes (1)

  • The feasibility of iSuite to create an electroanatomical map (EAM) of the heart during CMR-EP

    To establish whether the visualization by iSuite is correct we will compare the location visualized by the EAM with the reference images as produced by the default cine MRI sequences at the target ablation location just prior to the RF ablation. The definition of correct visualization is: good agreement between the two modalities (EAM and cine MRI) based on visual assessment of the treating electrophysiologist and the supervising CMR expert. When no consensus is reached than the visualization is coded 'incorrect'. This outcome will be dichotomized and coded as 'correct visualization' or 'incorrect visualization'. This categorical variable will be expressed as counts and proportion with 95% confidence interval (CI).

    Periprocedural

Secondary Outcomes (3)

  • Procedural success as measured by electrical and anatomical confirmation of a complete ablation lesion at the end of the procedure:

    Periprocedural

  • Procedural time

    Periprocedural

  • Complication rate

    Periprocedural

Interventions

iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.

Also known as: "iSuite"

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include all eligible patients who are already scheduled and thus eligible for CMR-guided electrophysiological procedure for the treatment of a cardiac rhythm disturbance in the MUMC+, albeit meeting the in- and exclusion criteria.

You may qualify if:

  • Already scheduled by the treating electrophysiologist for CMR-EP as standard care for the treatment of a cardiac arrhythmia.
  • Minimum age of 18 years old.
  • Written informed consent

You may not qualify if:

  • Participation in another investigational study that has not reached its primary endpoint.
  • Contraindication for MRI such as: metallic implant, body weight \> 130 kg, pregnancy, breast feeding women, known severe allergy to gadolineum contrast agents, renal failure with eGFR ≤ 30 mL/min/1,73m2.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht UMC+

Maastricht, Limburg, 6202 AZ, Netherlands

RECRUITING

Related Publications (4)

  • Hilbert S, Sommer P, Gutberlet M, Gaspar T, Foldyna B, Piorkowski C, Weiss S, Lloyd T, Schnackenburg B, Krueger S, Fleiter C, Paetsch I, Jahnke C, Hindricks G, Grothoff M. Real-time magnetic resonance-guided ablation of typical right atrial flutter using a combination of active catheter tracking and passive catheter visualization in man: initial results from a consecutive patient series. Europace. 2016 Apr;18(4):572-7. doi: 10.1093/europace/euv249. Epub 2015 Aug 27.

    PMID: 26316146BACKGROUND
  • Paetsch I, Sommer P, Jahnke C, Hilbert S, Loebe S, Schoene K, Oebel S, Krueger S, Weiss S, Smink J, Lloyd T, Hindricks G. Clinical workflow and applicability of electrophysiological cardiovascular magnetic resonance-guided radiofrequency ablation of isthmus-dependent atrial flutter. Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):147-156. doi: 10.1093/ehjci/jey143.

    PMID: 30307544BACKGROUND
  • Vergara GR, Vijayakumar S, Kholmovski EG, Blauer JJ, Guttman MA, Gloschat C, Payne G, Vij K, Akoum NW, Daccarett M, McGann CJ, Macleod RS, Marrouche NF. Real-time magnetic resonance imaging-guided radiofrequency atrial ablation and visualization of lesion formation at 3 Tesla. Heart Rhythm. 2011 Feb;8(2):295-303. doi: 10.1016/j.hrthm.2010.10.032. Epub 2010 Oct 27.

    PMID: 21034854BACKGROUND
  • Lichter J, Kholmovski EG, Coulombe N, Ghafoori E, Kamali R, MacLeod R, Ranjan R. Real-time magnetic resonance imaging-guided cryoablation of the pulmonary veins with acute freeze-zone and chronic lesion assessment. Europace. 2019 Jan 1;21(1):154-162. doi: 10.1093/europace/euy089.

    PMID: 29878090BACKGROUND

MeSH Terms

Conditions

Arrhythmias, Cardiac

Interventions

Bestrophins

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Chloride ChannelsIon ChannelsMembrane Transport ProteinsCarrier ProteinsProteinsAmino Acids, Peptides, and ProteinsEye ProteinsMembrane GlycoproteinsMembrane Proteins

Study Officials

  • S.M. Chaldoupi

    Maastricht UMC+

    PRINCIPAL INVESTIGATOR
  • Casper Mihl

    Maastricht UMC+

    PRINCIPAL INVESTIGATOR
  • J.E Wildberger, Prof. Dr

    Maastricht UMC+

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

January 18, 2021

First Posted

January 27, 2021

Study Start

January 4, 2021

Primary Completion

June 1, 2024

Study Completion

December 1, 2024

Last Updated

February 3, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

This is a small scale single center study and there is no plan to share IPD in order to ensure participant privacy, and the risk of invalid analysis. Data will be registered in the Castor EDC database by the investigator, after patient data has been anonymized. The principal investigator and involved investigators of the research team will have access to the source data and safeguard the code. The handling of personal data will comply with the General Data Protection Regulation and the Dutch Act on Implementation of the General Protection Regulation. Data and the key to the unique patient study number will be kept for 15 years after study end. During this single centre study, no data will be shared or transferred. Once the study has ended, we will ensure that all data are managed and securely stored. Data will be available for use in future research on cardiac arrhythmia. Qualified monitors of Clinical Trial Centre Maastricht will independently perform monitoring of the study.

Locations